TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02419508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Brinz/brim vehicle
Description: Inactive ingredients used as a placebo for masking purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue

Intervention type: DRUG
Group type: OTHER
Intervention: Prostaglandin analogue
Study: NCT03152682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GoodIdea
Description: Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GoodIdea
Description: Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
Study: NCT03789227

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ganglion impar block
Description: the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ganglion impar block
Description: the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ganglion impar block
Description: the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
Study: NCT03782935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prenatal multivitamin mineral supplement
Description: prenatal vitamin/mineral supplement with or without choline supplement
Study: NCT01980589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Study: NCT00386542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxigrip® trivalent inactivated influenza vaccine
Description: See full description elsewhere in this record.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip® trivalent inactivated influenza vaccine
Description: See full description elsewhere in this record.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip® trivalent inactivated influenza vaccine
Description: See full description elsewhere in this record.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal spacer on Biojector® 2000 jet injector
Description: See elsewhere in this record for full description.
Study: NCT03273218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tiger catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Judkins catheter
Study: NCT04066075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Low Vision Rehabilitation for use of magnification devices for near reading tasks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Low Vision Rehabilitation for use of magnification devices for near reading tasks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Vision Rehabilitation
Description: Low Vision Rehabilitation for use of magnification devices for near reading tasks
Study: NCT02711280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT01526083

Intervention type: OTHER
Group type: OTHER
Intervention: Lacosamide
Description: Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days

Intervention type: OTHER
Group type: OTHER
Intervention: Warfarin
Description: Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose
Study: NCT02797002

Intervention type: OTHER
Intervention: Assessment

Intervention type: OTHER
Intervention: Assessment
Study: NCT03998839

Intervention type: OTHER
Intervention: Community distribution of Sulfadoxine-pyrimethamine (SP)
Description: Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
Study: NCT00848562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Oral administration of nicorandil (15 mg/day)
Study: NCT02166944

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tamoxifen 40 mg daily for one year
Description: both arms with riluzole daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen 40 mg daily for one year
Description: both arms with riluzole daily
Study: NCT00196092

Intervention type: DEVICE
Group type: OTHER
Intervention: Roll-in
Description: Proctored entry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Surgical
Description: Surgery

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Risk
Description: Standard Endovascular repair

Intervention type: DEVICE
Group type: OTHER
Intervention: High Risk
Description: High Risk Endovascular repair.

Intervention type: DEVICE
Group type: OTHER
Intervention: Compassionate Use
Description: Endovascular repair for compassionate use patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment for females
Description: Endovascular repair in female patients

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard Risk Continued Access
Description: Continued Access Endovascular repair for standard risk patients.

Intervention type: DEVICE
Group type: OTHER
Intervention: High Risk Continued Access
Description: Continued Access Endovascular Repair for High Risk Patients.
Study: NCT01538238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: pazopanib 800mg qd until progression or unacceptable toxicity
Study: NCT04257760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care consultation outside standard of care
Description: The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
Study: NCT00851071

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Three 45 minute CBT sessions scheduled over a 3 month period.
Study: NCT01384214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: 750 U at Visit 1
Study: NCT02307370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turbo-Elite Laser Catheter
Description: Application of laser energy to remove blockage
Study: NCT01744132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aim 3: Contract
Study: NCT00171860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT03737773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glasses (prismatic lenses)
Study: NCT03374319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified amputation procedure
Description: A stair-step (BKA) or fishmouth (AKA) incision will be made. Tibial and fibular or femoral osteotomies will be performed. Segments of the tibialis anterior (TA), peroneus longus (PL), lateral gastrocnemius (LG) and tibialis posterior (TP) muscles will be isolated, as well as the quadriceps (Q) and hamstring (H) groups in the AKA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. The distal tibial and peroneal nerves will be redirected to skin patches in the distal or proximal thigh. Coaptation of the TA/LG, PL/TP and Q/H muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
Study: NCT00357760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: Given IV
Study: NCT03737773

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glasses (neutral)
Study: NCT01187537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Nerve Block
Description: 20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Femoral Nerve Block
Description: 20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Femoral Nerve Block
Description: 20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
Study: NCT01827384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given intravenous (IV)
Study: NCT02664623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individual dietary consultations
Description: Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dietary advice sheet
Description: At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dietary advice sheet
Description: At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio.
Study: NCT01827384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given by mouth (PO)
Study: NCT00667615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
Description: Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
Study: NCT01602588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg bd from 14 days post surgery until clinical or radiological progression

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Short Course radiotherapy
Study: NCT02019485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)
Description: Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)
Description: Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged-Release Formulation 2 (PR2)
Description: Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Prolonged-Release Formulation 2 (PR2)
Description: Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
Study: NCT03030846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise
Description: 18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: 8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
Study: NCT00732719

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Study: NCT01654679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wIRA irradiation
Description: wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: visible light only
Description: visible light application at a distance of 27cm from the skin surface with for 20 min.
Study: NCT00732719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Study: NCT00004156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1-KLH vaccine/QS21
Study: NCT03570112

Intervention type: DRUG
Intervention: SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
Description: sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
Study: NCT04345445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: IV infusion
Study: NCT02670265

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olimel Peri 2.5% ®
Description: During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic fluid (E153)
Description: Controls received 1l of isotonic fluid daily by intravenous route.
Study: NCT01617941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
Study: NCT00429585

Intervention type: DEVICE
Group type: OTHER
Intervention: reamed, interlocking intramedullary nail
Description: Standard of care device for tibia fracture repair; Randomized Treatment - Nail

Intervention type: DEVICE
Group type: OTHER
Intervention: locking periarticular plate
Description: Standard of care device for tibia fracture repair; Randomized Treatment - Plate
Study: NCT03639948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Injectable product
Study: NCT04160390

Intervention type: OTHER
Intervention: Biospecimen Collection-Blood
Description: Undergo collection of blood

Intervention type: OTHER
Intervention: Biospecimen Collection-Stool
Description: Undergo collection of stool
Study: NCT03024775

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat flour
Description: Wheat flour will be administered three times per day for 15 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat flour
Description: Wheat flour will be administered three times per day for 15 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (xylose) will be administered three times per day for 15 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (xylose) will be administered three times per day for 15 days.
Study: NCT01080885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Busy Bodies/Better Bites
Description: This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Spots/Safe Tots
Description: This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
Study: NCT04880928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eye injection (Mydrane)
Description: Mydrane 0.2 mg/ml + 3.1 mg/ml~+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eye drops (Phenylephrin)
Description: Phenylephrine 10%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eye drops (Tropicamid)
Description: Tropicamid 0,5%
Study: NCT03849339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D635
Description: Reference drug